Zinc Acetate Hydrate Supplementation versus Polaprezinc Supplementation for Improving Hypozincemia in Hemodialysis Patients: A Randomized Clinical Trial

Figure 5

Changes in the hemoglobin (Hb) level, erythropoiesis stimulating agent (ESA) dosage, and erythropoietin resistance index (ERI). The Hb level remains within 11.2–11.6 g/dL in the ZAH group and within 10.9–11.4 g/dL in the PPZ group until week 52, with significant differences between the two groups only at week 24. ESA use is consistently lower in the ZAH group than in the PPZ group during the observation period. However, no significant between-group difference was observed in ESA use except at 52 weeks. The ERIs of both groups show line graphs similar to their respective ESAs but were not significantly different throughout the observation period. (a) Hemoglobin level, (b) ESA dosage, (c) ERI.

(a)

(b)

(c)